Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05315713 · ClinicalTrials.gov registry record · Phase 1
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05315713 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 8 participants.
The verdict
NCT05315713, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previous lines of systemic therapy.
Interventions
- DRUG Atezolizumab
- DRUG Tiragolumab
- DRUG Mosunetuzumab SC
- OTHER Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2023-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05315713
The ClinicalTrials.gov registry entry for NCT05315713 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Atezolizumab is the first listed.
NCT05315713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05315713 about?
NCT05315713 is a clinical study titled "An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma". This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previ...
What is the current status of trial NCT05315713?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-05-10. Estimated completion is 2023-07-19.
What interventions are being tested in trial NCT05315713?
The interventions under investigation include: Atezolizumab (DRUG), Tiragolumab (DRUG), Mosunetuzumab SC (DRUG), Tocilizumab (OTHER).
Who is sponsoring clinical trial NCT05315713?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.